CA-ALVEO-TECHNOLOGIES
Alveo Technologies, Inc. (Alveo), a leader in molecular sensing and diagnostics with its proprietary be.well™ technology platform, today launched a web-based partner portal and suite of enablement software tools to further drive innovative partnerships onto the platform to co-develop and commercialize rapid, point of need diagnostic solutions across multiple life sciences industry sectors. Furthermore, its newest partnership with the Fraunhofer Institute for Cell Therapy and Immunology IZI extends the platform into the large animal veterinary sector. The institute belongs to the Fraunhofer-Gesellschaft, the world’s leading applied research organization.
Alveo has developed a rapid, handheld, reusable, and rugged multiplexed platform that pairs advanced molecular assays with cloud-enabled data analytics for highly accurate and sensitive real-time disease, pathogen and contaminant detection, analysis, and diagnosis. It utilizes Alveo’s globally patented loop-mediated isothermal amplification (LAMP) method for the direct electrical sensing of nucleic acid amplification. This portable molecular lab can deliver rapid testing at the point of need, for example, in doctor’s offices for various infectious diseases, in the field for crop testing, or on farms for livestock testing.
“True to our open-platform philosophy toward innovation, and our vision of making advanced molecular testing universally accessible, we are pleased to launch a web portal and software enablement suite that facilitates our current collaborations and opens the door to future partnerships across many new and underserved markets,” says Alveo CEO Shaun Holt. “We aim to work smarter to bring novel, accurate, and affordable molecular diagnostics to the point of need where actionable insights and outcomes can be significantly improved.”
“Alveo’s be.well™ platform is helping to solve some of the world’s toughest challenges in terms of healthcare access, food security, water and sanitation, and with future pandemic prevention measures,” Holt says.
In its mission to enable earlier detection of pathogens at the point of need, leveraging its open-platform approach, Alveo has partnered with companies in multiple industries around the world to co-develop and commercialize rapid molecular testing capabilities. Alveo’s phased partnerships can range from months to years depending upon the complexity and number of applications of interest. Depending on the extent of a partner’s in-house capabilities, Alveo can either complete the entire test development process with market and technical domain expertise from the partner in a Supported Partnership model, or lend its be.well™ expertise to the partner’s own research and development of assays in a Self-sufficient Partnership. The Partnership Portal facilitates collaboration and gives partners access to all research, training, and development resources required to bring a molecular diagnostic to market.
Fraunhofer IZI, based in Germany, is a world leader in the life sciences and with LAMP technology. Using Alveo’s be.well platform, Fraunhofer IZI will design novel assays within the veterinary space drawing on its deep experience in this area.
“We are impressed with the near-limitless possibilities of Alveo’s be.well™ platform and look forward to collaborating to build out their library of tests,” said Dr. Dirk Kuhlmeier, Head of the Diagnostics Department, Fraunhofer Institute of Cell Therapy and Immunology IZI. “Diagnostics is one of the four areas of focus for Fraunhofer Health and moving testing closer to the point of need is a strategic imperative for us.”
Partnership phases include defining the market and product requirements, primer screening and assay development, and transfer of the assay to the be.well™ Cartridge where it is optimized and validated through testing on Alveo’s IMPACT™ data analysis and testing software suite. Clinical trials and/or field studies are then conducted to verify the assay and validate the platform, Alveo develops and launches the be.well™ Mobile App, the partners collaborate on commercialization plans and Alveo manufactures the product.
Fraunhofer IZI joins a roster of commercialization partners including Barbados Investment and Development Corporation (Export Barbados (BIDC)), which brings the Caribbean nation’s top scientists and life sciences leaders into collaboration with Alveo in designing new assays in the areas of infectious disease, agriculture, veterinary, food, medicine, and aquaculture testing. Alveo has also partnered with agricultural sector leaders to design crop- and animal-specific assays to detect and analyze an even broader range of pathogens within the agricultural space, in the field, in real time.
About Alveo
At Alveo, we strive to improve outcomes by making molecular detection and diagnostics universally accessible – whether that means in the home, on the farm, in the clinic, or even within industrial processes. We understand the value of detecting pathogens earlier where decisions and results can be most effective and impactful. Alveo’s be.well™ platform technology encompasses a unique method of nucleic acid amplification coupled with our proprietary direct electrical sensors, enabling improved outcomes across numerous market sectors and verticals at the point of need. Our platform was designed from the bottom up to enable detection and diagnosis of pathogens earlier given its portability, ease of use, robust and rugged design, multiplexing capability, high accuracy, coupled with fast times to result. Cloud connected and Bluetooth enabled, advanced data and analytics are available for reportable diseases, and monitoring and surveilling of new and emerging pathogens. Our aim is to help customers and patients prevent or significantly limit the negative, destructive impact viruses, fungi, bacteria, and other pathogens can have on our planet. In doing so, we are providing actionable insights at lightspeed, improving health outcomes, saving time, reducing cost, and improving yields. With Be.well™, we Know Sooner, Act Faster™.
To learn more, visit https://alveotechnologies.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230711477764/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Delivers Record First Quarter Net Sales of 1.129 Billion USD, Including Strong Performance From Two Launches With Blockbuster Potential, and Confirms Full-Year Guidance24.4.2025 07:00:00 CEST | Press release
Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first quarter of 2025. Net sales: Achieved 1,129 million USD in net sales, up 8.3% year-on-year on a constant currency basis, primarily driven by volume, complemented by favorable mix Results ahead of expectations: Net sales benefited from focused execution, favorable phasing in Injectable Aesthetics, and stronger than expected ramp-up of Nemluvio Broad-based growth: Strong performance momentum across product categories and across geographies, with constant currency year-on-year growth of 9.9% for Injectable Aesthetics, 7.8% for Dermatological Skincare, and 4.9% for Therapeutic Dermatology, which includes net sales of 39 million USD for Nemluvio® (nemolizumab) Innovation, science and education leadership: Further advanced its category leadership in dermatology: with the launch of Nemluvio and Relfydess™ (RelabotulinumtoxinA),
Engelhart and e.optimum Strengthen Their Partnership With a Further Onshore Wind PPA, Supporting Germany’s Energy Transition24.4.2025 07:00:00 CEST | Press release
The Global Commodities and Renewable Energy Trader, Engelhart, is delighted to announce the signing of a further power purchase agreement (PPA) with e.optimum, one of Germany’s largest independent energy suppliers. Following the first PPA signed in January 2025, this new agreement secures renewable electricity from additional onshore wind turbines with a total capacity of approximately 167 MWfromJuly to December 2025. This is enough green power to supply around 31,000 households. This second PPA marks a significant expansion of the partnership between the two companies. It represents a 195% increase in contracted capacity, bringing the total from 86 MW to 253 MW of onshore wind power. Furthermore, the agreement contributes directly to Germany’s transition to a net zero-carbon economy by 2045. Matthias Seel, Senior Originator Corporate Customers Europe at Engelhart, commented: "The second PPA with e.optimum is another milestone in our joint partnership. Especially in uncertain economic
Textron Aviation Raises the Bar for Workforce Development With State-of-the-Art Career & Learning Center23.4.2025 22:00:00 CEST | Press release
Textron Aviation Inc. a Textron Inc. (NYSE: TXT) company, today announced its new Career & Learning Center is complete and fully operational serving prospective, current and future Textron Aviation employees. Strategically located on the company’s East Wichita Campus, this state-of-the-art facility expands the training footprint to more than 75,000 square feet and provides a world-class employee experience during the application, hiring, onboarding and training processes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250423874476/en/ Textron Aviation Career and Learning Center | Textron Aviation “The Textron Aviation Career & Learning Center is an important investment in building the next generation of aviation manufacturing, support and professional talent,” said Ron Draper, president and CEO. “Recruiting, hiring and training a world-class workforce is vital to our ability to provide the best aviation experience for our cu
TSMC Unveils Next-Generation A14 Process at North America Technology Symposium23.4.2025 20:40:00 CEST | Press release
Showcasing TSMC’s latest offerings for high performance computing, smartphone, automotive, and IoT applications TSMC (TWSE: 2330, NYSE: TSM) today unveiled its next cutting-edge logic process technology, A14, at the Company’s North America Technology Symposium. Representing a significant advancement from TSMC’s industry-leading N2 process, A14 is designed to drive AI transformation forward by delivering faster computing and greater power efficiency. It is also expected to enhance smartphones by improving their on-board AI capabilities, making them even smarter. Planned to enter production in 2028, the current A14 development is progressing smoothly with yield performance ahead of schedule. Compared with the N2 process, which is about to enter volume production later this year, A14 will offer up to 15% speed improvement at the same power, or up to 30% power reduction at the same speed, along with more than 20% increase in logic density. Leveraging the Company’s experience in design-tech
Veracode Delivers End-to-End Risk Coverage with New Tools: AI-Powered Dynamic Analysis Security Testing with External Attack Surface Management23.4.2025 17:42:00 CEST | Press release
Seamless Integration and Speed: Latest Innovations Empower Faster, Smarter, and Safer Software Security Veracode, a global leader in application risk management, today announced new capabilities to help organizations address emerging threats, giving security professionals better visibility and control in one place. The launch includes new AI-powered functionality in the Dynamic Application Security Testing (DAST)product and an External Attack Surface Management (EASM) capability. Together, they enable security teams to discover their entire attack surface and prioritize the most critical risk to streamline and simplify security scanning. “Security teams need to see and secure everything; not only what is inside their perimeter,” said Derek Maki, Head of Product at Veracode. “With our latest DAST capabilities and Application Risk Management platform enhancements, we’re helping organizations shift from vulnerability scanning to holistic risk management, to better identify risk residing i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom